By Rafiqul Islam
For most of the last decade, the weight-loss conversation ran through two drug names: semaglutide (sold as Ozempic and Wegovy) and, more recently, tirzepatide (Mounjaro and Zepbound). A third name is now moving through late-stage trials, and the early numbers have put it ahead of both. It is called retatrutide.
Retatrutide is an experimental injectable that produced up to 24% body-weight reduction in a mid-stage trial. It is not yet approved by the FDA. Here is what the drug is, what the data actually show, and why clinicians and patients are watching it closely.
Semaglutide works by mimicking a single gut hormone, GLP-1, which curbs appetite and slows stomach emptying. Tirzepatide adds a second target, GIP, and that combination pushed weight-loss figures higher. Retatrutide goes one step further and acts on three receptors at once: GLP-1, GIP, and glucagon.
The glucagon arm is the new piece. Beyond suppressing appetite, glucagon-receptor activity raises energy expenditure and appears to reduce fat stored in the liver. Researchers describe retatrutide as a "triple agonist," and that third mechanism is the leading theory for why its results have outpaced the drugs before it.
The headline figures come from a Phase 2 trial published in the New England Journal of Medicine in 2023. Adults with obesity who received the highest dose, 12 mg once weekly, lost an average of 24.2% of their body weight over 48 weeks. Some participants had not yet plateaued when the trial ended.
Those numbers sit above the established drugs. In the SURMOUNT-1 trial, tirzepatide produced roughly 20.9% weight loss at its top dose. In the STEP 1 trial, semaglutide produced about 14.9%. For a class of drugs where a few percentage points once counted as a breakthrough, a jump of this size is notable.
The trade-off is familiar to anyone following this drug class. The most common side effects were gastrointestinal: nausea, diarrhea, and vomiting, generally mild to moderate and most frequent while the dose was being raised. Slow titration, the practice of starting low and increasing gradually, is how trials kept those effects manageable.
Choosing between these medications is not simply a matter of picking the highest number. Availability, cost, injection schedule, and individual tolerance all matter, and retatrutide remains investigational while the other two are already prescribed. For readers who want to see the mechanisms and trial figures side by side, this a detailed comparison of retatrutide and tirzepatide lays out where each drug leads.
Retatrutide is currently in Phase 3 trials, the final stage before a manufacturer can seek approval. Until those results are in and regulators have reviewed them, the drug is not available by prescription, and any product marketed as retatrutide outside a clinical trial is unregulated.
That caution matters. Weight-loss demand has created a large market for compounded and gray-market versions of these peptides, sold without the dosing controls, purity testing, or medical supervision that clinical use requires. The promising trial data describe a monitored setting, not a vial bought online.
The short version: retatrutide looks like the most powerful weight-loss drug studied to date, and if Phase 3 confirms the earlier results, it could reset the benchmark again. For now it is a drug to understand and watch, not one to obtain.
This article is for general education and is not medical advice. Talk to a licensed healthcare provider before starting, stopping, or combining any medication.
References:
Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023 Aug 10. (PMID 37366315)
Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022 Jul 21. (PMID 35658024)
Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021 Mar 18. (PMID 33567185)
MBTpg